Objective: Amyotrophic lateral sclerosis is a progressive degenerative disease, which typically leads to death in 3 to 5 years. Neuronal cell death offers a potential target for therapeutic intervention. Ursodeoxycholic acid is a cytoprotective, endogenous bile acid that has been shown to be neuroprotective in experimental Huntington and Alzheimer diseases, retinal degeneration, and ischemic and hemorrhagic stroke. The objective of this research was to study the safety and the tolerability of ursodeoxycholic acid in amyotrophic lateral sclerosis and document effective and dose-dependent cerebrospinal fluid penetration.
A myotrophic lateral sclerosis (ALS) is a progressive degenerative disease, which typically leads to death within 3 to 5 years of symptom onset. 1 Although the pathogenesis of ALS is incompletely understood, putative mechanisms involved in motor neuron degeneration in ALS include oxidative damage, mitochondrial dysfunction, neuroinflammation, growth factor deficiency, and glutamate excitotoxicity. 1Y5 Several of these processes may produce neuronal degeneration either individually or in concert.
Several pharmacological agents that target these potential mechanisms have been moderately effective in experimental ALS but have not been successfully translated into effective treatments for humans with ALS. Only the glutamate modulator, riluzole, has demonstrated efficacy in clinical trials and is approved for treating ALS.
Although there is no clinical experience with ursodeoxycholic acid (UDCA) in the context of neurodegenerative illnesses, it has been used for decades as a treatment of cholestatic liver disease and for centuries as a treatment of a number of maladies in Chinese medicine. Ursodeoxycholic acid is approved by the United States Food and Drug Administration for the treatment of primary biliary cirrhosis. 6 The taurine conjugate of UDCA (tauro-UDCA [TUDCA]) was also effective in patients with primary biliary ciorrhosis. 7 Importantly, it has been demonstrated both in vitro and in vivo that TUDCA benefits certain acute and chronic neurodegenerative disorders that are associated with increased levels of cell death. In fact, TUDCA is a potent neuroprotective agent not only in a transgenic animal model of Huntington disease 8 but also for ischemic and hemorrhagic stroke. 9, 10 Tauro-UDCA improves neurological function while significantly preserving mitochondrial membrane stability and inhibiting caspase activation. Moreover, TUDCA improved the survival and function of nigral transplants in a rat model of Parkinson disease 11 and partially rescued a Parkinson disease model of C. elegans from mitochondrial dysfunction. 12 More recently, it has been shown that TUDCA profoundly suppressed apoptosis and preserved function and morphology of photoreceptor cells in mouse models of retinal degeneration, 13 reduced transthyretin deposition in a transgenic mouse model of familial amyloidotic polyneuropathy, 14 and protected from secondary damage after spinal cord injury in rats. 15 In this study, we treated 18 patients to evaluate the safety and tolerability of UDCA and to document effective and dosedependent cerebrospinal fluid (CSF) penetration. Our results demonstrate that UDCA administration is safe and tolerable and can penetrate into the central nervous system in a dosedependent manner.
METHODS

Patients and Sample Collection
Subjects were recruited from the ALS Clinic at the University of Minnesota. All had probable or definite ALS by the World Federation of Neurology criteria. 16 Subject characteristics are shown in Table 1 . For safety reasons, patients were required to have a forced vital capacity of at least 60% of the predicted value at study entry. The subjects were randomly assigned to receive UDCA (Axcan Pharma Inc, Quebec, Canada) at doses
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Clinical Neuropharmacology & Volume 33, Number 1, January/February 2010 www.clinicalneuropharm.com of 15, 30, and 50 mg/kg of body weight per day. Block randomization with block size 6 was used to ensure approximately equal assignment to each of the 3 doses. The drug was administered orally in 3 equal doses a day with meals. The dose was escalated daily for the first week to the target dose, and that dose was continued for an additional 3 weeks. The subjects were evaluated weekly for clinical adverse effects, and blood was obtained for laboratory testing and UDCA assay at each of these visits. Laboratory tests included urinalysis, complete blood cell count, serum electrolytes and creatinine, and aspartine and alanine aminotransferases. Subjects and investigators were blinded to the dose administered. The study was approved by the Institutional Review Board of the University of Minnesota and was conducted in accordance with the board's ethical standards and the Helsinki Declaration of 1975, as revised in 1983. All subjects provided informed consent for all assessments and procedures, including the lumbar puncture.
After 4 weeks of dosing, patients came to the research unit fasting, and blood was drawn for UDCA assay. The usual morning dose was then administered with a standard meal. Blood was then obtained 1, 2, 4, and 6 hours after dosing. Two hours after the dose, lumbar puncture was performed and CSF was obtained for UDCA assay. Serum was immediately obtained from each blood specimen, and serum and CSF were frozen at j4-C until the assays were performed. Because UDCA is present in human bile, banked CSF samples obtained from 5 subjects who did not receive UDCA were assayed as controls.
An interim analysis was performed after the CSF had been assayed on the first 12 patients. Based on these results, the intermediate dose of 30 mg/kg was eliminated for the final 6 patients who were equally distributed to high-or low-dose UDCA.
Bile Acid Analysis
Bile acids were extracted from 1-to 2.5-mL plasma or 2.5-to 6-mL CSF by liquid-solid extraction as previously described. 17 Bile acid conjugates were then solvolyzed, hydrolyzed, isolated, and analyzed as methyl-trimethylsilyl ethers by gas chromatography. Identification of bile acids was made on the basis of gas chromatography retention index relative to a homologous series of n-alkanes, and the chromatograms were compared with authentic standards. Identification was confirmed by mass spectrometry analysis of selected samples. Quantitation was achieved by comparing the peak height response of the individual bile acids with that obtained from the internal standard.
Assessment of Safety
Clinical and laboratory adverse events were assessed according to the National Institutes of Health Common Toxicity Criteria for drug evaluation.
Statistical Analysis
The sample size for this preliminary safety and tolerability study was intentionally limited to 18 subjects to avoid unnecessarily exposing subjects to risk from lumbar puncture. Analysis of variance (ANOVA) was used to test for differences between doses in mean serum and CSF UDCA concentrations at each time point. Wilcoxon rank sum tests were used for post hoc tests of median serum and CSF UDCA concentrations. Linear regression analysis was used to evaluate the association between serum and CSF UDCA concentrations. The Fisher exact test was used to test for significant associations between dose and adverse event rates. The Tukey adjustment for multiple comparisons was used for post hoc tests to preserve the overall experiment significance level at 0.05.
RESULTS
Ursodeoxycholic acid was well tolerated by all subjects at all doses (Table 2 ). All adverse events were assessed to be of grade 1 or 2 severity. The commonest adverse effects were gastrointestinal in nature; 7 subjects complained of constipation, 5 of loose bowel movements, 1 of nausea, and 1 of abdominal bloating. Symptoms were rated as mild by all subjects. No other adverse effect was seen in more than a single individual, and they were equally divided amongst doses. All patients completed the 4 weeks of treatment. No abnormal laboratory values were seen during the period of the study.
The mean serum concentrations of UDCA by dose at each time point are shown in Figure 1 . A stable serum concentration was seen between days 8 and 29 of daily dosing and was approximately proportional to the dose administered, although the differences in median concentration were significant only for the highest and lowest doses (P values ranged from 0.004 to 0.026). On day 29, the serum concentration rose rapidly after oral administration to a peak concentration at 1 hour with 15 and 30 mg/kg and at 2 hours with 50 mg/kg. Differences in median concentration between the highest and lowest doses were significant at all time points (P values ranged from 0.0006 to 0.011). At 6 hours the serum concentration was still above the predosing level for all doses. At the time of the interim analysis of the first 12 patients, the CSF concentration of UDCA showed trends toward a dosedependent increase, but the differences in mean CSF concentration of UDCA between 15 and 30 mg/kg and between 30 and 50 mg/kg daily were not significant, whereas the difference in mean CSF concentration of UDCA between 15 and 50 mg/kg was significant. The remaining 6 subjects were therefore equally assigned to either 15 or 50 mg/kg. The CSF concentration of UDCA was measured in the 18 subjects who received UDCA: 7 receiving 15 mg/kg, 7 receiving 50 mg/kg, and 4 receiving 30 mg/kg (Fig. 2 ) and in 5 subjects who had not received UDCA. The mean CSF concentration at 15 mg/kg was 86.69 nmol/L (range, 43.1Y165.6); at 30 mg/kg, it was 114.22 nmol/L (57.2Y201.4); and at 50 mg/kg, 191.11 nmol/L (105.7Y281.7). The difference in median CSF concentration of UDCA between 15-and 50-mg/kg doses was significant (P = 0.03). Ursodeoxycholic acid could not be detected in subjects who had not been exposed to the drug. There was a strong correlation between serum UDCA concentration 1 hour after dosing and the concentration in the CSF samples taken 2 hours after dosing (Fig. 3) , indicating that most (78%) of the variability in CSF concentration was explained by variability in serum concentration.
DISCUSSION
This pilot study shows that UDCA can be safely administered to patients with ALS. Gastrointestinal tract adverse effects were frequent but of mild degree. All other adverse events were rare. Neither grade 3 or 4 toxicities nor abnormalities in laboratory findings were seen. This observation in patients with ALS reflects the experience in the clinic in patients with liver diseases such as primary biliary cirrhosis, chronic active hepatitis, and cystic fibrosis. In addition, we show that UDCA is well absorbed after oral administration and, most importantly, crosses the blood-brain barrier in a dose-dependent manner.
Ursodeoxycholic acid has been widely used to treat cholestatic liver diseases. 6 Its safety, efficacy, and tolerability have been well characterized. In patients with liver disease, UDCA is well tolerated and without significant neurotoxic effects at 18 ). After oral administration, UDCA is incompletely absorbed, and peak serum levels are achieved in 30 to 50 minutes. 19 In its conjugated form, the serum half-life of UDCA is approximately 17 hours. Details of central nervous system penetration of UDCA are unknown; however, in vivo studies of TUDCA administered intraperitoneally suggest that it does penetrate the blood-brain barrier in rats and can produce effects on apoptotic processes and behavior. 8 In this study, we demonstrated a strong correlation between serum UDCA concentration 1 hour after dosing and the concentration in the CSF samples taken 2 hours after dosing. In addition, UDCA was not detectable in CSF of subjects who had not ingested the drug.
Tauro-UDCA was very effective in reducing striatal atrophy in pharmacologic and transgenic animal models of Huntington disease. 8 Tauro-UDCA also remarkably inhibited each of the amyloid-AYinduced apoptotic events in rat neuronal cells, in part, through activation of the phosphoinositide 3-kinase pathway. 20 Furthermore, TUDCA treatment modulated expression of certain Bcl-2 family members and nuclear factor-JB activity in hemorrhagic stroke rat brains. 9 In addition to its protective action at the mitochondrial membrane, TUDCA also activated the Akt-1/protein kinase B> survival pathway and induced Bad phosphorylation at Ser-136.
Apoptosis has been suggested as a pathogenic mechanism in neurodegenerative diseases including ALS. It was recently demonstrated that motor neurons of both sporadic and familial patients with ALS lack phospho-Akt and that motor neurons of mutant superoxide dismutase 1 mice lose activated Akt early in the disease, before the onset of clinical symptoms. 21 In this regard, therapies up-regulating phospho-Akt were suggested to be of clinical relevance. A role in motor neuron cell death has also been shown for the transcription factor p53, known to modulate expression of many proapoptotic genes, both in wobbler mice and in patients with ALS. 22 In this study, the use of a p53 inhibitor, pifithrin-alpha, in organotypic slice cultures of mouse spinal cord challenged with a toxic stimulus significantly reduced cell death. Recent clinical trials, however, have failed to demonstrate a positive effect of antiapoptotic treatment in ALS. Minocycline showed a harmful effect on the course of the disease. 23 TCH346, a blocker of the apoptotic pathway where glyceraldehyde 3-phosphate dehydrogenase is FIGURE 1. Mean peak serum UDCA concentration was achieved at 1 hour for the 15-and 30-mg/kg doses and at 2 hours for the 50-mg/kg dose after dosing on day 29. The difference in serum concentration between day 8 and day 29 predose was calculated for each subject. The Wilcoxon signed rank test (a nonparametric paired t test appropriate for small sample sizes) was used to test the null hypothesis of no change in median concentration from day 8 to day 29 predose. Within each dose group and overall, there was no significant change in median serum concentration between day 8 and day 29 predose. Analysis-of-variance models were used to test for differences in mean serum UDCA concentration at each collected time point. Because of small sample sizes in each dose, Wilcoxon rank sum tests of differences in median serum UDCA concentration were used for pairwise comparisons. P values less than 0.05 in ANOVA F test indicate that at least 2 of the dose groups had significantly different mean serum UDCA concentration. The Tukey adjustment for multiple comparisons identified significant median UDCA concentration differences between 15-and 50-mg/kg doses at all time points after day 1. Significant median differences in UDCA concentration between 30-and 50-mg/kg doses were identified at all time points on day 29 (except 1 hour after dosing).
FIGURE 2.
Mean concentration of UDCA in CSF increased with increasing UDCA dose. Cerebrospinal fluid UDCA concentration for the 50-mg/kg dose group was more than twice that for the 15-mg/kg dose group. Results of ANOVA identified a significant difference in mean CSF UDCA concentrations between at least 2 of the dose groups (P = 0.0158, F-test). Tukey post hoc comparisons, which adjust for multiple comparisons, indicate that mean CSF UDCA concentrations for 15-and 50-mg/kg dose groups are significantly different. Results of Wilcoxon rank sum tests (appropriate for small sample size comparisons) for pairwise comparisons of median CSF UDCA concentration indicate that 15-and 50-mg/kg dose groups are significantly different (P = 0.031).
FIGURE 3. Significant correlation between day 29 serum UDCA concentration 1 hour after dosing and day 29 CSF UDCA concentration 2 hours after dosing for subjects in the study. The R 2 for this relationship is 0.7815, indicating that serum UDCA concentration 1 hour after dosing explains 78% of the variability in CSF UDCA concentration 2 hours after dosing.
involved, showed no evidence of a beneficial effect on disease progression in patients with ALS. 24 This pilot study shows the safety and tolerability of UDCA in patients with ALS, even at doses considerably in excess of the recommended upper dosing limit. Ursodeoxycholic acid penetrates CSF in a dose-dependent manner. A longer-duration study of UDCA in ALS is planned to evaluate long-term safety and tolerability of the drug and to obtain preliminary information regarding any beneficial effect.
